Compare Figs Inc (FIGS) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Organon & Co. Common Stock — how do they compare? Figs Inc trades at $18.62 (market cap $2.99B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Figs Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 31 Days and Organon & Co. Common Stock for 0 Days on average.
| FIGS | OGN | |
|---|---|---|
Market Cap | $2.99B | $3.62B |
Volume | 6,721,481 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $18.63 | $13.81 |
52-Week Low | $7.38 | $5.70 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | $2.75B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS stock trades at $18.63, up 4.9% today, showing strong momentum with three consecutive quarterly earnings beats. The company demonstrates robust fundamentals with 68.9% gross margins and accelerating revenue growth from $556M in 2024 to projected $710M in 2026. Technical indicators show bullish momentum with the stock trading near resistance at $19, though RSI levels suggest potential overbought conditions. Recent news highlights international expansion success with 67% Q2 international sales growth and raised 2026 guidance.
The outlook remains positive with analyst consensus pointing to 26% upside potential to $18 target, though the premium valuation (P/E 54.6) requires continued execution. Key risks include rich valuation multiples and competitive pressures in healthcare apparel. The combination of strong earnings momentum, international growth, and bullish technicals supports further upside if the company maintains its growth trajectory.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
